I
31.83
-0.90 (-2.74%)
| Penutupan Terdahulu | 32.72 |
| Buka | 32.30 |
| Jumlah Dagangan | 325,740 |
| Purata Dagangan (3B) | 2,411,588 |
| Modal Pasaran | 3,978,902,528 |
| Harga / Pendapatan (P/E TTM) | 32.47 |
| Harga / Pendapatan (P/E Ke hadapan) | 10.44 |
| Harga / Jualan (P/S) | 3.21 |
| Harga / Buku (P/B) | 145.25 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Apr 2026 |
| Margin Keuntungan | -5.30% |
| Margin Operasi (TTM) | 25.56% |
| EPS Cair (TTM) | -0.050 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -6.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -23.00% |
| Nisbah Semasa (MRQ) | 0.880 |
| Aliran Tunai Operasi (OCF TTM) | 135.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 264.88 M |
| Pulangan Atas Aset (ROA TTM) | 12.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Indivior Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.4
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | 0.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.40 |
|
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.02% |
| % Dimiliki oleh Institusi | 89.09% |
| Julat 52 Minggu | ||
| Median | 48.00 (50.83%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Jan 2026 | 48.00 (50.82%) | Beli | 34.56 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| KINGSLEY STUART A | 32.27 | - | 940 | 30,334 |
| RYAN BARBARA | 31.86 | - | 39 | 1,259 |
| Jumlah Keseluruhan Kuantiti Bersih | 979 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 31,593 | |||
| Purata Pembelian Keseluruhan ($) | 31.99 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| RYAN BARBARA | Pengarah | 13 Mar 2026 | Beli (+) | 8 | 31.11 | 249 |
| RYAN BARBARA | Pengarah | 09 Mar 2026 | Beli (+) | 31 | 32.60 | 1,011 |
| KINGSLEY STUART A | Pengarah | 06 Mar 2026 | Beli (+) | 940 | 32.27 | 30,334 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 28 Jan 2026 | Pengumuman | Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ |
| 26 Jan 2026 | Pengumuman | Indivior Announces Completion of Redomiciliation to the United States |
| 08 Jan 2026 | Pengumuman | Indivior Provides Full-Year 2026 Financial Guidance and Business Update |
| 22 Dec 2025 | Pengumuman | Indivior Announces Inclusion in the S&P SmallCap 600® Index |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |